Business Context and Reporting Period
This Form 6-K filing by PolyPid Ltd. covers the month of March 2023. The Company, a foreign private issuer based in Israel, reported the closing of significant capital raising activities and an amendment to its existing credit facility.
Key Financial Metrics and Capital Events
- Underwritten Public Offering: Closed March 31, 2023. Issued 16,859,000 ordinary shares (including full exercise of the over-allotment option) at $0.42 per share. Aggregate gross proceeds were approximately $6.2 million, with net proceeds of approximately $6.5 million to the Company.
- Private Placement Offering: Closed March 29, 2023. Sold pre-funded warrants to purchase up to 10,357,139 ordinary shares at $0.4199 per warrant. Aggregate gross proceeds were approximately $4.4 million.
- Total Capital Raised: Aggregate gross proceeds from both offerings totaled approximately $11.4 million.
- Debt Restructuring: Amended a secured line of credit with Kreos Capital VI (Expert Fund) LP. The interest rate was set at 10.00%. A restructuring fee of 1.00% was due at closing, with an incremental 3.00% due at maturity.
Material Changes and Debt Terms
The filing details a material change to the Company's debt obligations. Under the amended Credit Line, 70% of remaining principal and interest repayments are deferred and will be repaid monthly from August 2024 to May 2026. Additionally, warrants previously issued to Kreos were repriced to an exercise price of $0.42 per ordinary share.
A "claw back" mechanism was introduced, triggered by future partnership agreements or additional financing. If triggered, the Company must pay a minimum of $1.5 million, not to exceed $3 million, to Kreos.
Outlook, Use of Proceeds, and Risks
Use of Proceeds: The Company intends to use net proceeds from both the Public and Private Offerings to fund ongoing clinical activities and the development of D-PLEX 100, working capital, and general corporate purposes.
Lock-Up Period: The Company and its officers and directors agreed not to sell or dispose of securities for 90 days following the closing of the Public Offering without the Underwriter's consent.
Regulatory Contingency: The exercise of the Pre-Funded Warrants is subject to an increase in the Company's authorized share capital. The Company intends to seek shareholder approval for this increase at its 2023 annual meeting.
Financial Performance: The filing text does not provide specific values for revenue, profit, cash flow, or operating margins for the period.
Investor Verification Checklist
- Verify the final net proceeds received after all offering expenses and underwriting discounts.
- Confirm the status of the shareholder vote required to increase authorized share capital for the Pre-Funded Warrants.
- Review the specific terms of the "claw back" mechanism in the amended Credit Agreement to understand potential future cash outflows.
- Monitor the progress of clinical activities for D-PLEX 100 as the primary use of the raised capital.
- Check for any subsequent filings regarding the exercise of the Pre-Funded Warrants.